ELI Lilly & Q3 2026 Results: Net Income $6.45B, Up 15.5% YoY
Eli Lilly reported significant growth for the third quarter of 2026, with revenue increasing to $24.40 billion from $17.60 billion in the prior year. Net income for the nine months ended September 30, 2026, rose to $20.94 billion, driven by strong operational performance despite a substantial $7.54 billion charge for acquired in-process research and development.
- Key figure
- Net income $6.45B · +15.5% YoY